A public biopharmaceutical company with over 20 years operation in China’s pharmaceutical industry is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives. The firm is interested in in-licensing clinical stage assets for development, while collaborative R&D can also be considered. Typical equity investments range from $2-3M per deal. The firm has partnered with companies in Japan, the US and Europe. The firm is currently looking for new opportunities globally with a focus on US and EU.

Currently, the firm is seeking therapeutics in oncology, ophthalmology, and nephrology. The firm is most interested in new formulation and is open to small molecule, biologics, biosimilars, and repurposed drugs. The firm currently focuses on assets in phase 2 clinical trials, while it can consider assets from pre-clinical to on-market stages.

The firm is seeking innovative assets that address large unmet medical need. The firm generally seeks development and/or commercialization rights in China and Southeast Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment platform with around €4B in assets under management spans both venture and private equity. Since its inception, the firm has completed 200+ investments. The firm’s latest fund, a dedicated healthcare and life science fund, targets venture and growth stage Tech-Enabled Medicine companies operating at the convergence of health, life sciences and technology. Investment sizes can range from $5M (Seed to Series A) to $50M (Crossover), with average initial check sizes expected to be around $10-15M, and a significant portion will be reserved for later rounds. The firm’s sweet spot is in Series B to C companies.

The firm invests globally across Asia, North America, and Europe (including Middle East). The firm is particularly interested in companies that want to expand to other geographic markets and assist companies to scale globally.

The firm will invest in six areas at the convergence of health, life sciences and technology:

1. Life science tools – tools enabling advanced diagnostics / treatment: automated cell manufacturing & supply chain management for cell therapy, single cell manipulation, multi-omics consumables & reagents
2. Diagnostics – enable more precise diagnostics, early detection, treatment support: clinical multi-omics, companion Dx, digital imaging / pathology with AI, clinical decision support systems
3. Clinical trial enablement – finding the right patient and supporting distributed trials: patient subpopulation selection, trial site matching, virtual / decentralized trials, continuous trial monitoring, real world evidence
4. Advanced Therapeutics – new modalities enabled by new technology: AI-driven drug discovery, cell & gene therapy, gene editing, microbiome, protein modulation, etc.
5. New care models – changing point of care & virtual treatments: telehealth, digital therapeutics, digital mental health, wearables, chronic disease monitoring solutions
6. Next-gen devices / materials – implantables enabled by novel materials / miniaturization, connected devices: biopolymers, non-invasive treatments, monitoring, closed loop therapies, robotic surgery, 3D printing

The firm likes to see strong management teams with proven track record and problem-solving skills or outstanding scientific founders.

The company should have innovation with impact, a clear development and regulatory approval pathway, and capital efficiency (defined timeline and budget and prudent approach to valuation). The firm can lead and co-invest depending on the investment opportunity, and seeks board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm is actively investing in early-stage life science companies, primarily from Series A to beyond. Typical investment size ranges between $5-20M USD, and the firm works together with its network of other active investment firms and family offices to form investment syndicates. The firm is focused on companies based in USA and Canada, but is open to evaluating highly promising companies beyond North America.

The firm invests in therapeutics and devices, and digital health to a much lesser extent. The firm will not consider wearables. With regards to therapeutics, the firm is most interested in clinical stage companies (pre-clinical will most likely be considered too early stage) in the anti-infective space. The firm does look at other modalities and indications given that they are fairly advanced clinical assets. In terms of medical devices, the firm will consider those that are very close to, or already gained FDA approval. The firm is agnostic in terms of subsectors and indications, but is most interested in technologies that address a large market and can be applied in a wide scale. The firm has reviewed technologies in ophthalmology, cardiovascular, and pulmonary indications with positive interest.

The firm has no specific company or management team requirements, though strong intellectual property is considered a huge plus. The firm generally acts as a co-investor, but also engages fellow investors in their network to syndicate investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An India-focused private equity firm makes early-growth investments in several sectors including the life sciences. The firm seeks to invest in Series A or B and generally invest USD 1-10 million per company. The firm  focuses on India-based companies, but it also invests in companies based outside of India as long as they have some presence in India.

In the life sciences, the firm is interested in therapeutics, specialty pharma, medical devices, diagnostics, healthcare IT, and services. The firm prefers products that require relatively shorter clinical trials. For therapeutics, the firm generally invests in products in pre-clinical stage and is indication agnostic, but typically does not consider orphan indications. For medical devices, the firm will consider all classes and generally looks for devices beyond proof-of-concept.

The firm can both lead or act as co-investor in syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.